A scalable framework for adherence support, symptom monitoring, education, and escalation when cancer treatment moves from the clinic into the patient’s daily life.
Cancer survivorship is often discussed as the phase that begins when active treatment ends. For a growing number of patients, however, there is no clear end date.
People may take endocrine therapy for years, receive targeted therapies at home, remain on maintenance treatment, or move on and off treatment while living with advanced cancer. They may no longer visit an infusion center regularly, yet they continue to manage medication schedules, side effects, uncertainty, financial pressure, and the wider physical and emotional consequences of cancer.
The National Cancer Institute defines survivorship as beginning at diagnosis and continuing throughout the balance of life. It includes people who are still receiving treatment, those living with stable or advanced disease, and those who are cancer-free.
For health systems, this creates an important delivery challenge: how do you provide consistent support when treatment is happening largely outside the clinic?
The most practical answer is not to add another visit for every patient. It is to create a structured, risk-based pathway that combines education, ongoing assessment, proactive follow-up, symptom monitoring, and clear escalation rules.
The Missing Middle Between Active Treatment and Traditional Survivorship
Traditional oncology workflows are strongest when treatment is highly visible. Infusions, radiation appointments, laboratory tests, and clinic visits create regular opportunities for assessment and intervention.
Oral and maintenance therapies shift much of that responsibility into the home.
Patients must take medications correctly, recognize emerging side effects, decide when symptoms are important enough to report, coordinate refills, manage interactions with other medications, and sustain treatment routines alongside work and family responsibilities.
At the same time, they may not identify with conventional post-treatment survivorship services because they are technically still receiving cancer treatment. They can therefore fall into a “missing middle”: no longer surrounded by the infrastructure of intensive treatment, but not fully included in programs designed for life after treatment.
This distinction is increasingly important as more people live with advanced cancer for extended periods. The NCI notes that some people with advanced or metastatic disease now live for years while continuously receiving treatment or moving on and off therapy. Common challenges include changing side effects, repeated testing, financial concerns, uncertainty about treatment effectiveness, and maintaining everyday life.
A survivorship model that waits for treatment completion may never reach these patients.
Oral Treatment Requires More Than Initial Education
Patient education at the start of therapy is essential, but it is not sufficient as a long-term support strategy.
The Oncology Nursing Society’s evidence-based guidance recommends that organizations consider adherence risk assessment, education, ongoing assessment, proactive follow-up, coaching, motivational interviewing, and structured oral anticancer medication programs. The guidance reflects a fundamental shift in oncology: as treatment moves from the clinic to the home, health systems need processes that continue after the prescription is issued.
A review of structured oral anticancer medication programs identified several recurring components:
education and counseling;
dedicated clinical contacts;
ongoing follow-up;
adherence and toxicity monitoring;
support with medication procurement and delivery;
cost and access interventions;
information technology; and
patient risk assessment.
These components extend beyond traditional medication teaching. They recognize that adherence is affected by symptoms, cost, beliefs, emotional health, changing routines, communication, and access to the care team.
They also place responsibility on the care system—not solely on the patient.
Adherence Risk Changes Over Time
Health systems should avoid treating medication adherence as a fixed patient characteristic.
A patient who understands and follows a regimen during the first month may struggle later because of cumulative side effects, a change in insurance coverage, treatment fatigue, depression, travel, caregiving responsibilities, or competing health conditions.
A 2025 multicenter cohort study followed patients beginning oral systemic anticancer therapy and identified three different adherence patterns. Most maintained or improved adherence, while approximately 17% experienced declining adherence over time. Lower income was associated with the declining-adherence group, although the study was relatively small and should not be generalized to every population.
The operational lesson is valuable even without applying the exact percentage broadly: a one-time assessment at treatment initiation will not identify every patient who later needs support.
Risk should be reassessed at clinically meaningful intervals and after major events such as a medication change, new toxicity, hospitalization, insurance disruption, disease progression, or change in the patient’s support system.
Technology Helps Most When It Is Connected to a Care Pathway
Digital tools can make ongoing support more scalable, but technology alone is not a complete adherence intervention.
A 2024 systematic review and meta-analysis evaluated four randomized trials involving 806 patients using mobile health applications alongside oral anticancer medications. The applications commonly included symptom reporting, medication reminders, treatment information, automated care-team alerts, and—in one study—structured nurse follow-up.
The analysis did not find a statistically significant improvement in medication adherence. It did, however, find lower symptom burden and a 25% lower relative risk of grade 3 or 4 toxicity among patients using the applications compared with usual care.
These findings suggest a more nuanced role for digital health. An application should not simply remind patients to take a medication. Its greater value may be in helping patients recognize and report symptoms earlier, giving teams visibility between visits, and triggering intervention when an issue requires human attention.
The technology should therefore sit inside an agreed clinical workflow. It should be clear:
what information patients are expected to report;
who reviews alerts;
which responses can be automated;
which concerns require clinical review;
how quickly the team is expected to respond; and
how unresolved issues are escalated.
The current ASCO–ONS safety standards address antineoplastic therapy across routes and care settings, reinforcing that moving medication administration away from the infusion center does not remove the need for consistent safety processes and quality oversight.
A Six-Part Model for Scalable Support
Health systems do not necessarily need to establish a new clinic to support this population. They do need a repeatable operating model with defined ownership.
1. Define who belongs in the pathway
The organization should decide which patients will receive structured remote support.
The initial cohort might include patients beginning a higher-risk oral anticancer agent, people on long-term endocrine therapy, patients receiving maintenance treatment, or those living with advanced cancer on prolonged therapy.
Eligibility should be based on clinical and operational priorities rather than an assumption that only people who have completed treatment qualify for survivorship support.
Starting with one clinic, tumor type, or treatment category can make implementation more manageable.
2. Complete a multidimensional baseline assessment
A useful baseline assessment extends beyond whether the patient understands the prescription.
It should consider:
medication complexity and interaction risks;
baseline symptoms and functional status;
cognitive or memory concerns;
emotional distress;
health literacy and language preferences;
medication cost and pharmacy access;
transportation and laboratory access;
caregiver or household support; and
comfort using digital tools.
The objective is not to label a patient as “adherent” or “nonadherent.” It is to identify likely barriers and tailor the amount and type of support accordingly.
A patient with a simple regimen, few symptoms, and strong support may need light-touch monitoring. Someone facing multiple medications, financial stress, significant toxicity, or limited social support may require more frequent contact.
3. Standardize treatment onboarding
Every patient should receive consistent, understandable guidance before managing treatment at home.
Onboarding should explain how and when to take the medication, what to do after a missed dose, which foods or medications may interfere with treatment, how refills work, what symptoms can be managed at home, and which warning signs require immediate contact.
Teach-back is more reliable than simply asking whether the patient understands. Patients should be able to describe the plan in their own words and know exactly how to reach the appropriate team.
Education should also address the longer-term experience. Patients need permission to report persistent fatigue, sleep problems, anxiety, sexual health concerns, cognitive changes, and disruptions to daily life—not only symptoms that appear medically urgent.
4. Use adaptive monitoring rather than a fixed schedule
Monitoring should be more frequent during treatment initiation, after dose changes, and when new symptoms emerge. It can become less intensive for stable patients and increase again when risk changes.
Brief digital check-ins can assess medication-taking concerns, side effects, pain, fatigue, sleep, mood, and functional changes. Automated reminders can prompt completion, while predefined thresholds can determine whether the patient receives self-management guidance or is routed to a professional.
This adaptive model is more sustainable than requiring the same level of staff attention for every patient.
It also supports earlier identification of problems that patients might otherwise wait to mention at their next scheduled appointment.
5. Create tiered escalation pathways
Not every concern requires an oncology visit.
A tiered model can route patients according to severity and type of need:
Routine support may include evidence-based education, medication reminders, symptom-management resources, group programming, lifestyle support, or peer connection.
Moderate concerns may trigger outreach from a nurse, pharmacist, navigator, rehabilitation professional, dietitian, or behavioral health provider.
Urgent or clinically significant concerns should be directed back to the oncology team through a clearly defined escalation pathway.
The health system should retain clinical governance over thresholds, emergency instructions, and response expectations. Digital support can help standardize routing, but it should not replace clinical judgment.
6. Measure whether the pathway is working
The number of messages or reminders sent is not, by itself, a meaningful outcome.
A practical dashboard could include:
percentage of eligible patients enrolled;
baseline and repeated adherence-risk assessments;
symptom trends;
check-in completion;
number and type of escalations;
time from alert to response;
treatment interruptions or dose changes;
referrals to supportive services;
patient-reported experience; and
disparities in participation or outcomes.
The NCI’s National Standards for Cancer Survivorship Care emphasize that survivorship programs should be supported by formal processes and evaluated using measures such as patient-reported outcomes, referral and completion data, functional outcomes, care experience, and relevant operational measures. The standards also recognize that survivorship services may be delivered on-site, through telehealth, or by referral.
Extending Support Without Adding Another Manual Work Queue
A scalable pathway should reduce repetitive work rather than create an additional inbox for oncology teams.
Most routine education, reminders, low-risk check-ins, and self-management support can be standardized. Staff attention can then be focused on exceptions: a concerning symptom, declining engagement, an access barrier, a significant emotional-health need, or a possible treatment-safety issue.
The After Cancer is designed to serve as this type of support layer. Health systems can use the platform to provide personalized education, structured programming, symptom tracking, virtual group support, moderated peer connection, and asynchronous guidance between clinical visits. Escalation pathways and partner-specific resources can be configured around the health system’s existing services and clinical protocols.
The aim is not to replace oncology nurses, pharmacists, navigators, or physicians. It is to help those teams maintain visibility and extend support without manually delivering every routine interaction.
Survivorship Care Should Follow the Patient, Not the Treatment Calendar
Patients do not stop experiencing survivorship needs because they are still taking an anticancer medication.
For many people, long-term treatment and survivorship occur at the same time. They are managing the clinical demands of therapy while also trying to work, care for family, exercise, sleep, maintain relationships, manage fear, and live as normally as possible.
Health systems can respond by moving beyond the binary division between “active treatment” and “after treatment.” A structured oral and maintenance therapy pathway can bring together medication safety, symptom management, adherence support, and whole-person survivorship care.
The strongest model is not one that adds frequent visits for everyone. It is one that combines standardized digital support with risk-based human intervention—making care more continuous for patients and more manageable for already-stretched teams.
To explore how The After Cancer could complement your oral therapy, maintenance treatment, or survivorship workflows, book a conversation with our team.
Sources
National Cancer Institute: Definition of Survivorship and Cancer Survivorship Resources.
National Cancer Institute: Coping With Advanced Cancer Long Term.
Oncology Nursing Society: Guidelines to Support Patient Adherence to Oral Anticancer Medications.
Oncology Nursing Society: Domains of Structured Oral Anticancer Medication Programs.
ASCO–ONS Antineoplastic Therapy Administration Safety Standards.
Chow and Tan: Effectiveness of Mobile Health Applications for Oral Anticancer Medications.
Perrin and colleagues: Medication Adherence Trajectories Among Patients Receiving Oral Anticancer Drugs.
National Standards for Cancer Survivorship Care.